# Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)

> **NCT01076088** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 744 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin 50 mg
- **DRUG:** Metformin 500 mg
- **DRUG:** Sitagliptin 100 mg
- **DRUG:** Placebo
- **DRUG:** Metformin 850 mg

## Key facts

- **NCT ID:** NCT01076088
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-15
- **Primary completion:** 2012-12-24
- **Final completion:** 2012-12-24
- **Target enrollment:** 744 (ACTUAL)
- **Last updated:** 2017-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01076088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01076088, "Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01076088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*